Godavari Drugs Ltd vs Senores Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Godavari Drugs Ltd is ₹ 123.32 as of 30 Apr 15:30 . The P/E Ratio of Godavari Drugs Ltd changed from 0 on March 2022 to 0 on March 2025 . This represents a CAGR of 0.0% over 4 yearsThe P/E Ratio of Senores Pharmaceuticals Ltd changed from 45 on March 2025 to 45 on March 2025 . This represents a CAGR of 0.00% over 1 years The Market Cap of Godavari Drugs Ltd changed from ₹ 0 crore on March 2022 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 4 yearsThe Market Cap of Senores Pharmaceuticals Ltd changed from ₹ 2637 crore on March 2025 to ₹ 2637 crore on March 2025 . This represents a CAGR of 0.00% over 1 years The revenue of Godavari Drugs Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Senores Pharmaceuticals Ltd for the Dec '25 is ₹ 178.34 crore as compare to the Sep '25 revenue of ₹ 167.17 crore. This represent the growth of 6.68% The ebitda of Godavari Drugs Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Senores Pharmaceuticals Ltd for the Dec '25 is ₹ 57.79 crore as compare to the Sep '25 ebitda of ₹ 54.92 crore. This represent the growth of 5.23% The net profit of Godavari Drugs Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Senores Pharmaceuticals Ltd changed from ₹ 10.91 crore to ₹ 33.58 crore over 7 quarters. This represents a CAGR of 90.11% The Dividend Payout of Godavari Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Senores Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Godavari Drugs Ltd

Godavari Drugs Limited is engaged in the business of manufacture of Active Pharmaceutical Ingredients (API) and drug intermediates, through its manufacturing facility at Nanded, Maharashtra, India..
Sulphamethoxazole (SMX), the main product of the company, is a widely used anti-bacterial drug enjoying good export demand. The Company incorporated in December, 1987, has multiple production blocks for API's, drug intermediates and fine chemicals. The company has expanded its SMX capacity from 540 tpa to 720 tpa, integrating backward into the manufacture of drug intermediates, sulphamethoxide (cap.: 450 tpa) and diethyl oxalate, DEO (cap.: 750 tpa), and diversifying into the manufacture of trimetroprim, TMP (cap.: 144 tpa). The diversification into TMP is beneficial as SMX and TMP are used in combination to treat a wide variety of infections.

About Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Limited was originally incorporated as 'Senores Pharmaceuticals Private Limited' through a Certificate of Incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.
Thereafter, the name of the Company was changed to 'Senores Pharmaceuticals Limited' upon conversion to a Public Limited Company and a fresh Certificate of Incorporation dated September 4, 2023, was issued by the RoC to the Company. Senores Pharma is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms.
The Regulated Markets business is focused on Regulated Markets of US and Canada.
The Company has adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the mid-market range and received approvals for 19 ANDAs.

FAQs for the comparison of Godavari Drugs Ltd and Senores Pharmaceuticals Ltd

Which company has a larger market capitalization, Godavari Drugs Ltd or Senores Pharmaceuticals Ltd?

Market cap of Godavari Drugs Ltd is 124 Cr while Market cap of Senores Pharmaceuticals Ltd is 4,138 Cr

What are the key factors driving the stock performance of Godavari Drugs Ltd and Senores Pharmaceuticals Ltd?

The stock performance of Godavari Drugs Ltd and Senores Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Godavari Drugs Ltd and Senores Pharmaceuticals Ltd?

As of May 4, 2026, the Godavari Drugs Ltd stock price is INR ₹123.32. On the other hand, Senores Pharmaceuticals Ltd stock price is INR ₹898.7.

How do dividend payouts of Godavari Drugs Ltd and Senores Pharmaceuticals Ltd compare?

To compare the dividend payouts of Godavari Drugs Ltd and Senores Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.